In view of the current situation (March 2020) with a rapid spread of the COVID-19 pandemic, we collect useful resources to facilitate information retrieval.

 

Advice and Guidelines:

Jin Y-H et al. (2020) A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Medical Research 7: 4

Thomas-Rüddel D et al. (2020) [Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020]. Anaesthesist 10.1007/s00101-020-00758-x (Article in German)
Coronavirus disease 2019 (COVID-19): update for anesthesiologists and intensivists March 2020 (English Version)

Resources collected by the European Society of Intensive Care Medicine (ESICM)

Waleed Alhazzani et al (2020) Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) Un-edited accepted proof, Intensive Care Medicine (date accessed: 25.03.2020)

Surviving Sepsis Campaign COVID-19 Guidelines - Short Summary, Crit Cloud (date accessed: 25.03.2020)

 

Clinical characteristics

Chen T et al. (2020) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368: m1091

Grasselli G et al. (2020) Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 10.1001/jama.2020.5394

 

Immunology

Mehta P et al. (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet https://doi.org/10.1016/S0140-6736(20)30628-0

Ritchie AI, Singanayagam A Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? The Lancet https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30691-7/fulltext (Reply to Mehta et al.)

Chen G et al. (2020) Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest 10.1172/jci137244

Lv H et al. (2020) Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. bioRxiv 10.1101/2020.03.15.993097: 2020.2003.2015.993097

Jeon S et al. (2020) Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. bioRxiv 10.1101/2020.03.20.999730: 2020.2003.2020.999730

Kox M et al. (2020) COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients. medRxiv 10.1101/2020.04.03.20049080: 2020.2004.2003.20049080

Xiong Y et al. (2020) Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging Microbes & Infections 9: 761-770

Giamarellos-Bourboulis EJ et al. (2020) Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe 10.1016/j.chom.2020.04.009

 

Host response

Blanco-Melo D et al. (2020) SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems. bioRxiv 10.1101/2020.03.24.004655: 2020.2003.2024.004655